These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 31273513)

  • 1. Low number of intrafollicular T cells may predict favourable response to rituximab-based immuno-chemotherapy in advanced follicular lymphoma: a secondary analysis of a randomized clinical trial.
    Budau L; Wilhelm C; Moll R; Jäkel J; Hirt C; Dölken G; Maschmeyer G; Neubauer E; Strauch K; Burchert A; Herold M; Neubauer A
    J Cancer Res Clin Oncol; 2019 Aug; 145(8):2149-2156. PubMed ID: 31273513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
    Papaioannou D; Rafia R; Rathbone J; Stevenson M; Buckley Woods H; Stevens J
    Health Technol Assess; 2012; 16(37):1-253, iii-iv. PubMed ID: 23021127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma.
    Chiu H; Trisal P; Bjorklund C; Carrancio S; Toraño EG; Guarinos C; Papazoglou D; Hagner PR; Beldi-Ferchiou A; Tarte K; Delfau-Larue MH; Morschhauser F; Ramsay AG; Gandhi AK
    Br J Haematol; 2019 Apr; 185(2):240-253. PubMed ID: 30767211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients.
    Xerri L; Huet S; Venstrom JM; Szafer-Glusman E; Fabiani B; Canioni D; Chassagne-Clément C; Dartigues-Cuilléres P; Charlotte F; Laurent C; Gelas-Dore B; Bolen CR; Punnoose E; Bouabdallah R; Brice P; Morschhauser F; Cartron G; Olive D; Salles G;
    Hum Pathol; 2017 Jun; 64():128-136. PubMed ID: 28414090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study.
    Herold M; Haas A; Srock S; Neser S; Al-Ali KH; Neubauer A; Dölken G; Naumann R; Knauf W; Freund M; Rohrberg R; Höffken K; Franke A; Ittel T; Kettner E; Haak U; Mey U; Klinkenstein C; Assmann M; von Grünhagen U;
    J Clin Oncol; 2007 May; 25(15):1986-92. PubMed ID: 17420513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.
    Huet S; Tesson B; Jais JP; Feldman AL; Magnano L; Thomas E; Traverse-Glehen A; Albaud B; Carrère M; Xerri L; Ansell SM; Baseggio L; Reyes C; Tarte K; Boyault S; Haioun C; Link BK; Feugier P; Lopez-Guillermo A; Tilly H; Brice P; Hayette S; Jardin F; Offner F; Sujobert P; Gentien D; Viari A; Campo E; Cerhan JR; Salles G
    Lancet Oncol; 2018 Apr; 19(4):549-561. PubMed ID: 29475724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study.
    Rossi D; Bruscaggin A; La Cava P; Galimberti S; Ciabatti E; Luminari S; Rigacci L; Tucci A; Pulsoni A; Bertoldero G; Vallisa D; Rusconi C; Spina M; Arcaini L; Angrilli F; Stelitano C; Merli F; Gaidano G; Federico M; Palumbo GA
    Haematologica; 2015 Apr; 100(4):517-24. PubMed ID: 25596266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of rituximab plus bendamustine chemotherapy on the immune system in patients with refractory or relapsed follicular lymphoma and mantle cell lymphoma.
    Ito K; Okamoto M; Ando M; Kakumae Y; Okamoto A; Inaguma Y; Tokuda M; Yanada M; Yamada S; Emi N
    Leuk Lymphoma; 2015 Apr; 56(4):1123-5. PubMed ID: 24828861
    [No Abstract]   [Full Text] [Related]  

  • 9. Decreased expression of T-cell-associated immune markers predicts poor prognosis in patients with follicular lymphoma.
    Rai S; Inoue H; Sakai K; Hanamoto H; Matsuda M; Maeda Y; Haeno T; Watatani Y; Kumode T; Serizawa K; Taniguchi Y; Hirase C; Espinoza JL; Morita Y; Tanaka H; Ashida T; Tatsumi Y; Nishio K; Matsumura I
    Cancer Sci; 2022 Feb; 113(2):660-673. PubMed ID: 34837284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absolute B cell counts in blood predict long-term response in follicular lymphoma patients treated with rituximab without chemotherapy.
    Junlén HR; Lockmer S; Kimby E; Wahlin BE
    Ann Hematol; 2020 Oct; 99(10):2357-2366. PubMed ID: 32808106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial.
    Canioni D; Salles G; Mounier N; Brousse N; Keuppens M; Morchhauser F; Lamy T; Sonet A; Rousselet MC; Foussard C; Xerri L
    J Clin Oncol; 2008 Jan; 26(3):440-6. PubMed ID: 18086798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recovery of central memory and naive peripheral T cells in Follicular Lymphoma patients receiving rituximab-chemotherapy based regimen.
    Milcent B; Josseaume N; Petitprez F; Riller Q; Amorim S; Loiseau P; Toubert A; Brice P; Thieblemont C; Teillaud JL; Sibéril S
    Sci Rep; 2019 Sep; 9(1):13471. PubMed ID: 31530876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era.
    Blaker YN; Spetalen S; Brodtkorb M; Lingjaerde OC; Beiske K; Østenstad B; Sander B; Wahlin BE; Melen CM; Myklebust JH; Holte H; Delabie J; Smeland EB
    Br J Haematol; 2016 Oct; 175(1):102-14. PubMed ID: 27341313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial.
    Watanabe T; Tobinai K; Wakabayashi M; Morishima Y; Kobayashi H; Kinoshita T; Suzuki T; Yamaguchi M; Ando K; Ogura M; Taniwaki M; Uike N; Yoshino T; Nawano S; Terauchi T; Hotta T; Nagai H; Tsukasaki K;
    Lancet Haematol; 2018 Nov; 5(11):e520-e531. PubMed ID: 30389034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
    Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W;
    Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis.
    Vidal L; Gafter-Gvili A; Salles G; Bousseta S; Oberman B; Rubin C; van Oers MH; Fortpied C; Ghielmini M; Pettengell R; Witzens-Harig M; Dreger P; Vitolo U; Gomes da Silva M; Evangelista A; Li H; Freedman L; Habermann TM; Shpilberg O
    Eur J Cancer; 2017 May; 76():216-225. PubMed ID: 28336303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
    Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune infiltrate diversity confers a good prognosis in follicular lymphoma.
    Tsakiroglou AM; Astley S; Dave M; Fergie M; Harkness E; Rosenberg A; Sperrin M; West C; Byers R; Linton K
    Cancer Immunol Immunother; 2021 Dec; 70(12):3573-3585. PubMed ID: 33929583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of rituximab plus first-line mitoxantrone, chlorambucil, prednisolone and interferon-alpha as maintenance therapy in follicular lymphoma.
    Herold M; Scholz CW; Rothmann F; Hirt C; Lakner V; Naumann R
    J Cancer Res Clin Oncol; 2015 Sep; 141(9):1689-95. PubMed ID: 25804839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Follicular Lymphoma: The Role of the Tumor Microenvironment in Prognosis.
    Sugimoto T; Watanabe T
    J Clin Exp Hematop; 2016; 56(1):1-19. PubMed ID: 27334853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.